<a href="https://www.fiercebiotech.com/biotech/after-decade-hype-najat-khan-bringing-recursion-back-down-earth" hreflang="en">After a decade of hype, Najat Khan is bringing Recursion back down to earth</a>
Najat Khan, the new CEO of Recursion Pharmaceuticals, is focused on transforming the company's AI-driven drug development potential into tangible products for patients, emphasizing a disciplined approach following a decade of unmet promises under her predecessor. With promising early data on their cancer candidate REC-1245 and ongoing collaborations with major pharmaceutical companies, Khan aims to streamline clinical development and harness their comprehensive platform to address significant medical needs.
Recursion Pharmaceuticals, under Najat Khan's leadership, is leveraging AI to rapidly develop drug candidates, as evidenced by the swift 18-month progression of their cancer drug candidate REC-1245 from target identification to IND-enabling studies. This approach highlights a significant reduction in compound synthesis compared to industry standards, suggesting a more efficient drug discovery process. For those interested in AI drug discovery, observing Recursion's model of integrating AI with in-house patient recruitment could offer insights into accelerating clinical development timelines and improving trial site selection.